
    
      The study will enroll 3 cohorts of 8 healthy subjects ≥55 and ≤80 years of age at the
      Clinical Pharmacology Unit (CPU) and 1 cohort of 12 AD subjects ≥55 and ≤80 years of age.
      Subjects in cohorts 1-3 will receive the study drug or placebo for 10 consecutive days while
      confined to the CPU. AD patients in cohort 4 will receive the study drug or placebo for 28
      days as outpatient. Blood samples samples will be collected for pharmacokinetic measurements.
    
  